6-apb 6-apb 6-apb (6-(2-aminopropyl)benzofuran) is an empathogenic psychoactive compound of the substituted benzofuran and substituted phenethylamine classes. 6-apb and other compounds are sometimes informally called "benzofury" in newspaper reports. it is similar in structure to mda, but differs in that the 3,4-methylenedioxyphenyl ring system has been replaced with a benzofuran ring. 6-apb is also the unsaturated benzofuran derivative of 6-apdb. it may appear as a tan grainy powder. while the drug never became particularly popular, it briefly entered the rave and underground clubbing scene in the uk before its sale and import were banned. it falls under the category of research chemicals, sometimes called "legal highs." because 6-apb and other substituted benzofurans have not been explicitly outlawed in some countries, they are often technically legal, contributing to their popularity. 6-apbclinical dataatc codenonelegal statuslegal status ca: schedule iii de: anlage ii (authorized trade only, not prescriptible) uk: class b identifiers iupac name 1-(1-benzofuran-6-yl)propan-2-amine cas number286834-85-3 n 286834-84-2 (hcl)pubchem cid9794343chemspider7970110 yunii285ve60914comptox dashboard (epa)dtxsid401010105 chemical and physical dataformulac11h13nomolar mass175.231 g·mol−13d model (jsmol)interactive image smiles nc(c)cc1=cc(oc=c2)=c2c=c1 inchi inchi=1s/c11h13no/c1-8(12)6-9-2-3-10-4-5-13-11(10)7-9/h2-5,7-8h,6,12h2,1h3 ykey:fqdamylmqqkprx-uhfffaoysa-n y ny (what is this?) (verify) pharmacology pharmacodynamics 6-apb is a serotonin–norepinephrine–dopamine reuptake inhibitor (sndri) with ki values of 117, 150, and 2698 nm for the norepinephrine transporter (net), dopamine transporter (dat), and serotonin transporter (sert), respectively. in addition, 6-apb not only blocks the reuptake of these monoamine neurotransmitters but is also a releasing agent of them; that is, it is a serotonin-norepinephrine-dopamine releasing agent (sndra). in addition to actions at the monoamine transporters, 6-apb is a potent full agonist of the serotonin 5-ht2b receptor (ki = 3.7 nm), with higher affinity for this target than any other site. moreover, unlike mdma, 6-apb shows 100-fold selectivity for the 5-ht2b receptor over the 5-ht2a and 5-ht2c receptors. it is notably both more potent and more selective as an agonist of the 5-ht2b receptor than the reference 5-ht2b receptor agonist, bw-723c86, which is commonly used for research into the 5-ht2b receptor. aside from the 5-ht2b receptor, 6-apb has also been found to bind with high affinity to the α2c-adrenergic receptor subtype (ki = 45 nm), although the clinical significance of this action is unknown. 6-apb showed little other affinity at a wide selection of other sites. the potent agonism of the 5-ht2b receptor makes it likely that 6-apb would be cardiotoxic with chronic or long-term use, as seen with other 5-ht2b receptor agonists such as the withdrawn serotonergic anorectic fenfluramine. pharmacokinetics the pharmacokinetics of 6-apb have not been studied, however, some information can be extracted from user reports. these suggest a slow onset of 40–120 minutes. the drugs peak effects last 7 hours, followed by a comedown phase of approximately 2 hours, and after effects for up to 24 hours. metabolism although limited literature is available, there is some data on metabolism of 6-apb in rats. its phase i metabolism involves hydroxylation of the furan ring, then cleavage of the ring, followed by a reduction of the unsaturated aldehyde from the previous step. the resulting aldehyde may then take two paths. it is either oxidized to a carboxylic acid or reduced to an alcohol, and then hydroxylated. phase ii metabolism consists of glucuronidation. the most prevalent metabolites in rats were 3-carboxymethyl-4-hydroxyamphetamine and 4-carboxymethyl-3-hydroxyamphetamine. adverse effects acute psychosis has been associated with recreational use of 6-apb in combination with the synthetic cannabinoid jwh-122. reagents results 6-apb and its structural isomer 5-apb have been tested with a series of agents including: marquis, liebermann, mecke, and froehde reagents. exposing compounds to the reagents gives a colour change which is indicative of the compound under test. compound marquis mecke mandelin liebermann froehde gallic ehrlich hofmann simon's folin 6-apb purple purple to black purple to black black purple brown orange light orange no reaction light orange 6-apb succinate purple purple to black purple to black black purple brown faint orange no reaction no reaction light orange 6-apb succinate is reported to be practically insoluble in chcl3 as well as very minimally soluble in cold water. a batch seized by the dea contained a 2:1 ratio of succinate to 6-apb. synthesis synthesis of 6-apb and its structural isomer 4-apb the synthesis by briner et al. entailed refluxing 3-bromophenol with bromoacetaldehyde diethylacetal and sodium hydride to give the diethyl acetal, which then was heated with polyphosphoric acid to give a mixture of bromobenzofuran structural isomers: 4-bromo-1-benzofuran and 6-bromo-1-benzofuran. the isomers were separated by silica gel column chromatography, then converted to their respective propanone derivatives, and then reductively aminated to give 6-apb and 4-apb, both of which were converted to their hcl ion pairs for further examination. dosage and duration based on anecdotal reports, the dosages for 6-apb are the following: dosage oral threshold 15 mg light 15 - 60 mg common 60 - 90 mg strong 90 - 120 mg heavy 120 mg + duration oral onset 30 - 60 minutes (or more) come up 60 - 120 minutes peak 3 - 4 hours offset 2 - 3 hours total 7 - 10 hours after effects 6 - 48 hours reagent results exposing compounds to the reagents gives a colour change which is indicative of the compound under test. the following test results are from protestkit. compound marquis mecke mandelin liebermann froehde gallic ehrlich hofmann simon's folin 6-apb purple purple to black purple to black black purple brown orange light orange no reaction light orange 6-apb succinate purple purple to black purple to black black purple brown faint orange no reaction no reaction light orange law canada in 1999, amphetamines were changed from schedule iii to schedule i as a result of the safe streets act. some have speculated that 6-apb's structure qualifies it as a schedule i drug as an analog of mda. in 2014, a study funded by the canadian institutes of health research noted that 6-apb "may or may not be legal in canada depending on how one interprets the current act" and that it could be purchased for academic purposes without an exemption from health canada. the study also noted how, unlike the mdma it often serves as a replacement for in countries like the us, 6-apb's benzofuran structure does not make it a direct analogue of amphetamine despite similarities in effects. united states 6-apb is not scheduled at the federal level in the united states, but it may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the federal analog act. france 6-apb is unscheduled in france. germany 6-apb is illegal in germany since the 17th of july, 2013, when it was added to anlage ii of the betäubungsmittelgesetz. italy 6-apb is illegal in italy. luxembourg in luxembourg, 6-apb is not cited in the list of prohibited substances. therefore, it is still a legal substance. netherlands 6-apb is not listed under the opium law or the medicine act in the netherlands, and thus currently legal. new zealand and australia certain countries contain a "substantially similar" catch-all clause in their drug law, such as new zealand and australia. this includes 6-apb as it is similar in chemical structure to the class a drug mda, meaning 6-apb may be viewed as a controlled substance analogue in these jurisdictions. sweden in sweden, as of 27 december 2009 6-apb is classified as "health hazard" under the act lagen om förbud mot vissa hälsofarliga varor (translated act on the prohibition of certain goods dangerous to health). uk on june 10, 2013 6-apb and a number of analogues were classified as temporary class drugs in the uk following an acmd recommendation. this means that sale and import of the named substances are criminal offences and are treated as for class b drugs. on november 28, 2013 the acmd recommended that 6-apb and related benzofurans should become class b, schedule 1 substances. on march 5, 2014 the uk home office announced that 6-apb would be made a class b drug on 10 june 2014 alongside every other benzofuran entactogen and many structurally related drugs.